Compare Medpace Holdings Inc (MEDP) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Plby Group Inc — how do they compare? Medpace Holdings Inc trades at $528.29 (market cap $15.08B), while Plby Group Inc trades at $1.22 (market cap $139.87M). The key difference: Medpace Holdings Inc is far larger — about 107.8× Plby Group Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | PLBY | |
|---|---|---|
Market Cap | $15.08B | $139.87M |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $2.71 |
52-Week Low | $308.88 | $1.11 |
Enterprise Value | $14.55B | $287.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
PLBY Group trades at $1.21, up 3.42% with a market cap reflecting a P/S ratio of 1.02. The company shows improving fundamentals with five consecutive quarters of positive adjusted EBITDA and narrowing losses, though it remains unprofitable with negative ROE. Technical indicators signal bearish momentum despite neutral oscillators. Recent developments include Russell index inclusion and a strategic share repurchase program.
The outlook remains cautious due to persistent net losses and high debt levels, but operational improvements and brand repositioning offer potential upside. Key risks include execution challenges in licensing growth and competitive pressures in the leisure sector. Analyst consensus is strongly bullish with 75% buy ratings, suggesting confidence in the turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
